Salbutamol is usually administered as a racemic mixture but little is known about the enantioselectivity of salbutamol pharmacokinetics in the lung. This study was designed to investigate enantiomer concentrations in lung tissue after inhaled dosing.
Introduction
Salbutamol (INN, BAN) is a chiral compound usually administered via inhalation as 50:50 racemic (rac-) mixture of two enantiomers (stereoisomers) which are molecules with nonsuperimposable mirror images (analogous to the right and left hands). Salbutamol has one chiral centre resulting in (S)-and (R)-enantiomers. Unlike physicochemical processes, in living biological systems, individual enantiomers can differ significantly in their specific structure-activity related effects. Typically, these effects are found with transporters, drug receptors and metabolism enzymes highly relevant to pulmonary delivery [3] . Disposition following inhaled delivery involves processes that are both potentially enantioselective and physicochemical processes that are not.
The β2-adrenoceptor pharmacological activity of salbutamol resides in the (R)-enantiomer while (S)-salbutamol is generally considered to be pharmacologically inert at this target. There are convincing in vitro and animal in vivo studies that have shown (S)-salbutamol to be associated with a range of adverse airways effects. Relative to (R)-salbutamol, (S)-salbutamol elevates intracellular Ca 2+ [4] , enhances contraction of isolated human bronchial tissue [5] , increases airway responsiveness [6] , and promotes eosinophil activation [7] . (S)-salbutamol increased the contraction of isolated bronchial rings from equine airways induced by carbachol, and increased bronchial hyperreactivity to histamine [8] .
Continuous exposure to rac-salbutamol and (S)-salbutamol in guinea pigs increases bronchial hyperreactivity in response to stimuli, which appears to be partly mediated through sensory nerves [9] . Currently, however, the general consensus is that (R)-salbutamol offers no advantage over rac-salbutamol given the absence of clear clinical evidence to the contrary.
With regard to pharmacokinetics, blood levels of (S)-salbutamol are typically greater than the active (R)-salbutamol due to the faster elimination of the latter [10] . Salbutamol delivered by inhalation is absorbed systemically and partially metabolised (20-60%) by the enzyme catecholamine sulfotransferase (SULT1A3) before elimination in urine as unchanged drug and the major metabolite, 4-Osulfate. The common single nucleotide polypmorphism of SULT1A3 does not appear to be an important determinant of pharmacokinetics, at least in humans [11] . In repeated dosing studies in humans, the (S):(R) ratio in urine and blood increases over time [12] due to differences in the elimination half-life of the enantiomers.
Despite salbutamol being on the market for over 40 years, there are no published data on (R)-and (S)-salbutamol levels in the lung tissue after either oral or inhaled dosing, so lung compartment residence time between enantiomers is not known in any species. The possibility of accumulation of (S)-salbutamol relative to (R)-salbutamol in the lung, with the potential for adverse effects, has not been definitively addressed. Indirect assessment of enantioselective salbutamol metabolism, by comparison of the relative proportion of (R)-salbutamol in plasma following intravenous, oral and inhaled administration of rac-salbutamol, has demonstrated a small difference following inhalation [13] . This finding was attributed to either intestinal metabolism of the small percentage of the swallowed fraction of the inhaled dose where absorption was not prevented by charcoal or, alternatively, to clinically insignificant low levels of enantioselective presystemic lung metabolism.
In this manuscript, we describe for the first time the application of an enantioselective ultra high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) assay to directly measure salbutamol enantiomers in pulmonary epithelial lining fluid (PELF), central and peripheral lung tissue in a horse model after inhaled dosing. This approach allowed us to determine whether (S)-salbutamol accumulates in PELF and lung tissue and if enantioselective presystemic lung metabolism does indeed occur. Direct analysis of drug in PELF, as reported here, offers significant potential to allow for a greater understanding of the enantioselective bronchopulmonary pharmacokinetics of β-2 agonists, as well as application to other drug classes.
Methods

Equine drug administration
The study protocol was approved by the Animal Care and Ethics Committee (Charles Sturt University) ACEC 15/039. Twelve light breed horses (three Standardbred mares, five Standardbred geldings, two Thoroughbred mares, one Thoroughbred gelding and one Thoroughbred-Quarter Horse cross gelding) were used in the study. The horses ranged in age from 3 to 8 years (mean ± standard deviation [SD], 4.7 ± 1.6 years), and weighed from 370 to 554 kg (mean ± SD, 465.3 ± 56.1 kg). Horses were recruited via convenience sampling from a research herd kept outdoors in paddocks, and each underwent a veterinary physical examination prior to receiving medication. Each horse was led into an examination crush and sedated (xylazine 0.5 mg kg -1 and acetylpromazine 0.02 mg kg -1 ) administered by intravenous injection into the jugular vein. A jugular catheter was placed to facilitate peripheral blood collection. The upper respiratory tract, including nose, nasopharynx and trachea, was assessed by passage of a flexible video endoscope (external diameter 10 mm) through the ventral nasal meatus and into the trachea. The procedure was well tolerated after sedation and with application of a nose twitch. Horses with increased tracheal secretions (> grade 1) or with increased mucus in their nose or nasopharynx were removed from the study and only healthy horses free of clinical evidence of respiratory disease were included. Horses received a single dose of inhaled rac-salbutamol (Ventolin, GlaxoSmithKline Pty Ltd, Victoria, Australia) of 1000 μg ml -1 delivered by inhalation. For each horse, a total of 10 actuations ('puffs') were administered to deliver the nominated dose into the spacer whilst the device was held over the horse's nostril, with the release of medication timed to coincide with inhalation.
PELF
PELF sampling was adapted from similar techniques first used in human subjects [14] and subsequently applied to equine studies [15] . To obtain PELF samples, cotton tip swabs were attached to the distal end of a nasogastric tube, sheathed in PVC tubing (1.2 cm external diameter, 1.8 m length) and inserted via the nose and into the trachea until wedged in the airway. The swab ( Figure 1 ) was then advanced a further distance (~5 cm) to press against the airway wall for a timed collection of 60 s, before retrieval via the sheath. The swab was then retracted from the PVC sheath tube, removed and placed in an Eppendorf tube before storage at -20°C until analysis. Timed PELF collection was performed at 2, 5, 10 and 15 min following administration of the full inhalation dose. The mass of PELF collected was determined by weighing each postsampling wet swab compared to the same swab oven dried (4 h at 50°C) after chemical extraction.
Central lung bronchial biopsy
A bronchial biopsy was obtained from the bifurcation of primary and/or secondary bronchi under endoscopic visualisation, at 20 min (± 4.5 min) following administration of inhalation medication and following completion of PELF sampling. The sampling time for central lung tissue was chosen for practicality as it was not possible to take a bronchial biopsy while the PELF swab sampling tube was in place. A small biopsy instrument was passed through the instrument port of the endoscope and advanced to the distal part of the trachea and into the right or left mainstem bronchus. One tissue sample of approximately 0.5 × 1 × 1 mm was obtained and stored frozen at -20°C ready for drug extraction and quantitation. (R)-and (S)-salbutamol results were normalised to the yield of pulmonary tissue determined by two different methods; protein content (ng mg -1 ) using Bradford assay and mass (ng g -1 ) by weighing biopsies.
Peripheral lung percutaneous pulmonary biopsy
A percutaneous pulmonary biopsy was obtained from the right side of the horse, at the level of the 10-12th intercostal space, according to previously published techniques [16] Figure 1
Sampling device used for collecting pulmonary epithelial lining fluid consisting of a cotton swab attached to a nasogastric tube, inserted inside a sheath made from a flexible polyvinyl chloride tube. The swab was extended approximately 50 mm to press against the airway wall to absorb pulmonary epithelial lining fluid at 25 (±2) min following administration of inhalation medication. Prior to sedation, ultrasound was used to demonstrate the ventral pulmonary margin at this level, where the lung overlies the liver. Hair was clipped and the skin aseptically prepared and a small bleb (~0.5 ml) of lignocaine applied. Following PELF sampling and endoscopic bronchial biopsy, a Tru-cut biopsy instrument (14G, 8 cm) was used to obtain a single sample of lung tissue (usually obtained as a slender piece of tissue, approximately 0.5 mm diameter × 1 mm length) which was stored frozen at -20°C until analysis. A small square of stretch selfadhesive gauze was placed over the incision site for 6 to 12 h. (R)-and (S)-salbutamol results were normalized to the yield of pulmonary tissue determined by two different methods; protein content (mg kg -1 ) using Bradford assay and mass (ng g -1 ) by weighing biopsies.
Blood sampling
Venous blood samples were collected via the jugular catheter at time points (2, 5, 10, 15, 20 and 25 min) selected to coincide with respiratory samples as described above. Fluid in the lumen of the catheter was aspirated and discarded, and samples collected into lithium heparin Vacutainers (Becton, Dickinson and Company, NJ, USA) and stored on ice prior to centrifugation. Plasma was aspirated and stored frozen at -20°C for analysis. Horses were returned to a box or small yard for 2-4 h following sampling to ensure no adverse effects. Thereafter they were monitored daily for 7 days before return to the research herd.
UPLC-MS/MS enantioselective assay
All analyses were undertaken using a Waters Acquity H-class UPLC system (Waters Corporation, Milford, MA, USA). Chromatography was performed using an Astec Chirobiotic T chiral column (4.6 × 250 mm × 5 μm particles; Sigma-Aldrich). The UPLC was coupled to a Waters Xevo triple quadrupole mass spectrometer (Waters Corporation). Analyses were undertaken using multiple reaction monitoring (MRM) in positive electrospray ionization mode with sample preparation modified from previous work [11, [17] [18] [19] including elimination of the solid-phase extraction step. In brief, calibration standards were prepared at concentrations of 1, 2, 5, 10, 20 ng ml -1 unlabelled rac-salbutamol in 200 μl drug free horse plasma. Internal standard rac-salbutamol-D3 (3-hydroxymethyl-D2, α-D1; Medical Isotopes, Inc., Pelham, NH, USA; 4 ng) was added to each plasma sample (200 μl) and calibration standard in an Eppendorf centrifuge tube. Dilute ammonia solution (200 μl; pH 9) was then added to each sample and vortex mixed (final pH~8), before the addition of 1000 μl of HPLC grade ethyl acetate. This was vortex mixed for 1 min and then centrifuged at 15 000g for 5 min. The organic supernatant was transferred to a glass autosampler vial, from which the solvent was evaporated under nitrogen at 40°C. The residue was reconstituted using 100 μl of methanol and vortex mixed prior to analysis via UPLC-MS/MS. Lung biopsy samples were ground using a glass mortar and pestle with 250 μl dilute ammonia solution (pH 9) and 4 ng rac-salbutamol-D3. Grinding was continued after the addition of 1000 μl ethyl acetate. This mixture was transferred to an Eppendorf centrifuge tube, vortex mixed for 1 min and centrifuged at 15 000g for 5 min. The organic phase was transferred to a glass vial and evaporated to dryness under nitrogen at 40°C. A fresh aliquot of 1000 μl ethyl acetate was used to rinse the pestle, and the ground tissue was extracted with this solvent a second time in a similar manner. Combined dried extracts were reconstituted in 100 μl methanol for analysis. The cotton head of each PELF swab was cut from its stick and placed in an Eppendorf centrifuge tube and weighed. After the addition of 4 ng rac-salbutamol-D3, the swab was extracted with 1000 μl methanol by soaking overnight and vortex mixing. The methanol extract was transferred to a glass vial, reduced to dryness under nitrogen at 40°C and reconstituted in 100 μl methanol for analysis. The extracted swabs were dried to constant weight to estimate PELF mass.
The UPLC was operated with a mobile phase consisting of 100% methanol with 0.5% acetic acid and 0.1% ammonium hydroxide. Elution was isocratic for 12 min. The flow rate was 0.8 ml min -1 and the column was held at room temperature. Injection volume was 50 μl. Electrospray ionization was performed with a capillary voltage of 2.76 kV, a cone voltage of 22 V and individual collision energies for each MRM transition, as described below. The desolvation temperature was 450°C, nebulizing gas was nitrogen at 950 l h -1 and cone gas was nitrogen at 50 l h 
Assay performance
For tissue determinations, the lower limit of quantification (LLoQ) was largely determined by the mass of tissue obtained, with lower concentrations achieved with larger mass biopsies. For lung biopsy based on a mean mass of 6.5 mg, the LLoQ was 46 pg mg -1 and 29 pg mg -1 for (R)-and (S)-salbutamol respectively. All tissue samples had measurable levels of salbutamol enantiomers with signal to noise ratio 10. For plasma and PELF, the LLoQ was 0.12 ng ml -1 and 0.20 ng ml -1 for (R)-and (S)-salbutamol respectively. For ratio comparisons, ng ml -1 (plasma) was considered equivalent to ng g -1 (PELF and tissue). Precision (%RSD) for lung tissue (R)-and (S)-salbutamol was 3.4 and 1.2% respectively; PELF precision (%RSD) for (R)-and (S)-salbutamol was 2.4% and 2.4% respectively; plasma precision (%RSD) was 4.1% and 2.8% respectively. All matrices met acceptance criteria for accuracy (<10% deviation), recovery >50% and estimate of linearity with r 2 > 0.998.
Statistical methods
Differences in systemic plasma levels of (R)-and (S)-salbutamol were assessed by area under the concentrationtime curve up to 25 min (AUC 0-25 min ) and C max using paired Student t test with AUC determined using the trapezoidal rule. Differences between plasma and PELF enantiomers at each time point were assessed using Holm-Sidak multiple comparison t test. Tissue levels were nonparametric and differences between central and peripheral lung tissue were assessed using Wilcoxon matched-pairs signed rank test. Enantioselectivity in each sample type was determined using log of (S):(R) ratio with one-sample t test against a hypothetical value of 0 (no enantioselectivity) with log transformation used to account for lack of symmetry with ratios <1. Analyses were performed using GraphPad Prism 6 for Mac OSX (GraphPad Software Inc, CA, USA) with results of p < 0.05 considered statistically significant. Based on the log (S):(R) ratio of unlabelled:deuterated racemic standards of -0.00057 ± 0.01120 (mean ± SD), with α = 0.05 and β = 0.80 and a sample size of 12 we were able to detect a mean paired difference of 2.4% between enantiomers.
Results
PELF
The swab technique resulted in good yields of PELF (mean ± 95%CI) 57 ± 10 mg equivalent to around 50 μl from each swab, which was sufficient to detect drug. Time series from one horse were removed from the data analysis. This decision was made due to PELF levels that were within one SD of the mean for all other samples at 2 min, but rapidly increased to 62-fold higher at 5 min (18 100 ng g -1 ) and 8-fold higher at 10 and 15 min. These aberrant results were considered possibly due to either contamination of the end of the sampling tube, or slow dissolution of a larger inhaled drug particle impacted on the epithelium in the vicinity of the swab. The same horse did not display outlier data points for either lung tissue or plasma samples. For the remaining horses, there was rapid clearance of drug from the airway lumen with PELF levels decreasing around 50% over 15 min from mean ± 95%CI (R)-and (S)-salbutamol PELF concentrations of 389 ± 189 ng g -1 and 378 ± 177 ng g -1 respectively down to 194 ± 93 ng g -1 and 182 ± 81 ng g 
Lung tissue
Levels of enantiomers were detected in all biopsies, however, normalisation based on mass alone was difficult for the bronchial biopsy sampling. During the procedure, the biopsy was removed from the lung, but required washing with saline to transfer to the sample container. Tissue matrix in three samples disintegrated in solution upon transfer, therefore protein content was also used to standardise the tissue yield. Correlation between protein content and tissue mass was less than expected (r 2 = 0.39) so statistical analyses for bronchial biopsies were undertaken with both tissue mass (n = 9) and tissue protein (n = 12). For the central lung bronchial biopsies, the mean ± 95%CI biopsy mass was 6.5 ± 4.7 mg while for peripheral lung percutanous biopsy, the mass was 6.2 ± 2.6 mg. Protein concentration in central lung bronchial biopsy homogenates was 268 ± 77 μg ml -1 while for peripheral lung percutanous biopsy, the concentration was 822 ± 128 μg ml -1 .
Salbutamol enantiomers were higher (around 17-fold) in the central lung compared to the peripheral lung for both (R)-salbutamol (P = 0.016) and (S)-salbutamol (P = 0.016) when standardised by both weight and protein respectively (Figure 3 ). Mean ± 95%CI central lung levels of drug were 875 ± 945 vs. 49.5 ± 12 ng g -1 in the peripheral lung for (R)-salbutamol and central lung levels 877 ± 955 vs. 50.9 ± 12 ng g -1 (S)-salbutamol respectively with these values normalised by weight. There was no evidence of stereoselectivity for central lung with a mean ± 95%CI log (S):(R) ratio of 0.002 ± 0.006 (P = 0.59), however, the peripheral lung did display enantioselectivity but of a small magnitude (2.3%) with mean ± 95%CI log (S):(R) ratio of 0.010 ± 0.007 (P = 0.02).
Blood
Plasma levels demonstrated rapid enantioselectivity with both mean ± 95%CI AUC 0-25 min of 10.2 ± 2.1 and 12.8 ± 2.0 ng ml Levels (mean ± 95% confidence interval) of salbutamol enantiomers in pulmonary epithelial lining fluid (PELF) of horses following a single dose of inhaled rac-salbutamol of 1000 μg ml -1 (10 actuations of 100 μg dose) delivered by inhalation
Discussion
The study found no enantioselectivity in PELF or central lung tissue, and only minor enantioselectivity in the peripheral lung. In fact, the ratio of enantiomers in the lung was surprisingly close to unity in the central lung regions and PELF, as shown in Figure 5 . Pulmonary drug delivery is determined by deposition of drug onto the airway surface, mainly in the central lung, which may occur through impaction, sedimentation or diffusion [20] . Once deposited on the lung surface, the particulate drug dissolves into the PELF, with the dissolution rate largely determined by physicochemical properties [21] . As the processes of impaction, sedimentation, diffusion and dissolution are physicochemical in nature, it is not expected they would be enantioselective. However, unlike physicochemical processes, enantiomers can differ significantly in specific structure-activity relationships required for effect in living biological systems. Typically, enantioselectivity is observed with transporters, drug receptors and metabolism enzymes, hence there is potential for drug uptake from the airway lumen to be enantioselective, either via selective tissue uptake into the lung and subsequent metabolism, or via metabolism within the PELF [3] . Although enantioselectivity was not apparent in PELF or central lung tissue over the time frame of this study, peripheral lung samples demonstrated minor enantioselectivity, with an (S):(R) of around 1.02. Plasma levels of (S)-salbutamol were higher than (R)-salbutamol, as expected, but plasma enantioselectivity and presence of blood in peripheral biopsy samples could not easily account for the observed enantioselectivity. The salbutamol tissueplasma partition coefficient for peripheral lung (K p ) was around 100-fold for both enantiomers, so using a simple estimate the difference in (S):(R) AUC 0-25 min of 25% in plasma would account for only approximately 0.25% of the observed difference in tissue ignoring blood contained Figure 3 Central lung (bronchial biopsy) and peripheral lung (percutaneous biopsy) levels of salbutamol (SALB) enantiomers following a 1000 μg inhaled dose sampled at 20 and 25 min respectively, normalized by tissue mass. Open circles represent (R)-salbutamol and closed circles represent (S)-salbutamol. Inset A is a magnified display of levels less than 100 ng g -1 found in the peripheral lung.
Salbutamol enantiomer were higher (around 17-fold) in the central lung compared to the peripheral lung for both (R)-salbutamol (P = 0.016) and (S)-salbutamol (P = 0.016) respectively. *P < 0.05
Figure 4
Plasma levels of salbutamol enantiomers in horses following a 1000 μg inhaled dose demonstrated enantioselectivity with both mean ± 95%CI AUC 0-25 min of 10.2 ± 2.1 and 12.8 ± 2.0 ng ml -1 .
min (P = 0.0039) and C max of 0.52 ± 0.15 and 0.59 ± 0.18 ng ml -1
(P = 0.0095) for (R)-and (S)-salbutamol respectively. *P < 0.05
Figure 5
Ratio of salbutamol enantiomers in pulmonary epithelial lining fluid, central and peripheral lung tissue and plasma over the time course of the investigation. Enantioselectivity is shown in plasma (5, 10, 15 min) and peripheral lung at 25 min. *P < 0.05 within the sample itself. Drug deposition and PELF solubilisation in PELF and central lung samples are both likely to be non-enantioselective physiochemical processes. By contrast, concentration in peripheral lung tissue may be determined by uptake mechanisms into tissue including organic cation transport (OCT) [22] and β2-receptor internalisation [23] , as well as local lung metabolism, which are all more likely to be stereoselective processes.
In the lungs, the main metabolizing enzymes are the Phase I cytochrome P450 isoforms (CYPs), as well as Phase II sulfotransferases (SULTs), UDP-glucuronosyltransferases (UGTs), and glutathione S-transferases (GSTs). In general, the overall contribution of lung metabolism is minor compared to the liver. Lung metabolism is influenced by factors such as drug delivery, residence time within lung tissue and pulmonary elimination processes [24] . Somers et al. [24] reported that lung:liver expression ratio of Phase I CYP enzymes (including CYP3A4, CYP2D6, 2C19, 2C9, and 2A6) were <0.025, while expression of relevant Phase II enzymes SULT1A3/4 and UGT2A1 were around 2-5. A stereoselective sulfoconjugation metabolism study in human lung epithelial cells also demonstrated intrinsic clearance of (S)-salbutamol to be slower than (R)-salbutamol [25] .
The role of potentially enantioselective OCT mechanisms in salbutamol pulmonary clearance remains equivocal. Valenzuela et al. [26] have demonstrated simultaneous passive diffusion and active absorption of salbutamol, together with an active capacity-limited efflux mechanism. Other investigations into human OCT proteins have suggested stereoselective binding with drugs closely related to salbutamol, including acebutolol, fenoterol, atenolol, propranolol and isoproterenol [27, 28] . Furthermore, it is apparent that concomitant corticosteroid use may interfere with removal of cationic drugs by OCT in the airway with the effect more apparent with formoterol compared to salmeterol [29] .
Analysis of the regional deposition of aerosol generally refers to central vs. peripheral lung deposition, however, there are no standard methods for defining these pulmonary regions [30] and care should be used when comparing central: peripheral drug ratios between studies. The central area usually accounts for around 20-30% of total lung area, but 40-60% of total lung deposition for monodisperse particles in the 3-6 μm particle size range (via two-dimensional planar imaging using γ-scintigraphy) depending on method [30] . Central lung tissue levels of drug were higher than peripheral lung, consistent with deposition of larger particles by inertial impaction and sedimentation in central airways. Scintigraphic studies have shown that penetration of peripheral lung fields decreases with increasing particle size, and also depends on how the peripheral lung field is defined, with less penetration at the extreme periphery [30] . However, relative to the diameter of equine airways, particle size in the current study, using an metered dose inhaler (MDI) optimized for human delivery, is likely to be small and hence to favour penetration to more peripheral airways. Our central:peripheral ratio of 17 is therefore likely to be reflective of percutaneous sampling at the extreme periphery of the lung, rather than the larger area normally attributed to the peripheral pulmonary region.
Further differences in central:peripheral salbutamol ratio are possible due to administration methods. Animals will breathe with a relatively consistent tidal volume during the administration procedure without a large/forced inhalation (with volumes potentially increased as much as inspiratory reserve volume) that would normally be encountered with a human using a metered dose inhaler during administration. Hence, the central:peripheral ratio may be relatively higher in a sedated animal (such as our experiment) compared to a human patient where forced inspiration during the administration of an inhaler should result in greater drug delivery to the lung periphery. Indeed in humans, Schmekel et al. [12] found that after inhaled administration via endotracheal catheter under anaesthesia, salbutamol t max was delayed compared to inhalation via a metered dose inhaler indicating differences in pulmonary deposition.
Although bronchoalveolar lavage (BAL) has been used extensively for determination of antibiotic levels in the lung following oral delivery [31] , direct analysis of drug concentration in PELF using absorption methods offers advantages over BAL techniques and is a growing area of interest, for example in recent work with biomarkers [32] . With BAL, standardization and accurate quantification is difficult [33, 34] , and determination of drug concentrations requires the use of a marker to correct for dilution and variable recovery of PELF. Disease status and choice of dilution marker can influence results [35] , and the area BAL fluid is collected from can vary [36] , whereas PELF targets the central lung. The relatively consistent level of drug observed in PELF in the current study suggests that salbutamol may offer potential as a dilution marker for other pulmonary biomarkers from a variety of matrices such as BAL, exhaled breath condensate, PELF and sputum.
Drug concentration in PELF in the present study was consistent with previous in vitro studies [8] , suggesting that the dose and administration technique used represents a rational basis for treatment. Matera et al. [8] reported mean 50% effective concentration relaxant effects observed between 0.20 and 0.55 μm for (R)-salbutamol after histamine provocation, compared to central lung (3.7 μm) and peripheral lung (0.21 μm) levels observed in our study. The half-life estimate of PELF concentration of 15 min was based on a reduction in concentration to around 50% at the completion of the ELF sampling phase. PELF consists of water (96%), salts, phospholipids, mucins, with a pH = 6.6 with the lipids and proteins aiding solubilization of less water-soluble drugs. Water-soluble drugs such as salbutamol (computer modelled log octanol:water partition coefficient (logP) at pH 7.4~-1.3) will solubilise quickly into the mainly aqueous PELF, while drugs that are less water soluble (for example the long acting β2-agonists formoterol logP = 0.04 and salmeterol logP = 3.6) will take longer to dissolve in PELF and are therefore more likely to be subject to airway mucociliary clearance, which is in the order of 2 cm min -1 in horses [37] . PELF has an estimated total volume of 10-30 ml in healthy adult humans, and varies in thickness from around 5-10 μm in the conducting airways to less than 0.1 μm in the alveoli, and therefore rates of dissolution, based on Fick's Laws of diffusion, will vary between regions of the lung [38] . Horses are unquestionably excellent models for asthma compared to rodent models, which must be sensitized experimentally to an antigen, with inflammation sometimes transient and clinical signs generally absent [39] . Horses are one of few species affected spontaneously by reversible airway obstructive conditions like asthma. In horses, recurrent airway obstruction (RAO or heaves) is characterized by very similar clinical symptoms to asthma, late phase hyperresponsiveness, similar inflammation profile, airway smooth muscle remodelling resembling asthma, and is managed by treatments including β2-agonists, cromoglycate and corticosteroids [39] [40] [41] . Physiological advantages of horses include their large size and poorly developed airway protective reflexes, allowing direct sampling of PELF and bronchial epithelial biopsy from their conducting airways at low welfare cost, with animals tolerating all sampling procedures well. Percutaneous lung biopsy is a routine clinical procedure, used with relative safety to the animal and no adverse effects were observed in healthy horses used in the current study. Despite the emerging acceptance of equine asthma models, there is still limited information on functional similarities between equine and human metabolic enzymes, or equine lung metabolism more specifically. Expression of Phase I CYP3A isoenzymes (responsible for salmeterol metabolism) have been reported in the horse lung [42] . A cross species study into Phase II conjugation using pyrene as a substrate marker has demonstrated sulfation and glucuronidation (relevant to salbutamol and formoterol respectively) as dominant conjugation detoxification pathways in both humans and horses [43] This current study was acute in nature and the clinical relevance of different enantiomer levels in peripheral lung remains uncertain, but there is clearly the potential for accumulation of the (S)-salbutamol enantiomer, and subsequent risk of increased adverse airway effects including bronchial hyperreactivity [6] [7] [8] [9] , with repetitive or chronic dosing. As repeated dosing leads to accumulation of (S)-salbutamol relative to (R)-salbutamol in plasma [12] , similar divergence of lung tissue enantiomer concentrations might be anticipated with chronic dosing, and warrants further investigation in ongoing work using this model. Good clinical practice dictates that short-acting β2-agonists should not be overused in asthma, minimising the risk of accumulation. However, the issue of chronic use of the more lipophilic long-acting β2-agonists is of concern. Formoterol does exhibit stereoselectivity, both pharmacodynamically with (R,R)-formoterol more active at the β2-adrenoceptor [44] , as well as pharmacokinetic enantioselectivity in plasma [45] and urine [46] , with slower elimination of (S,S)-formoterol. (S,S)-formoterol does also appear to have potential to be proinflammatory [47] .
In conclusion, PELF sampling via swab absorption in horses offers sufficient yield allowing direct detection of drug and, combined with tissue sampling, is a valuable model to investigate bronchopulmonary pharmacokinetics of a range of drugs such as β2-agonists, corticosteroids and antibiotics. Salbutamol did not demonstrate enantioselective levels in PELF or central lung tissue following acute dosing. However, rapid enantioselectivity was found in the plasma with some minor enantioselectivity in the peripheral lung. Given that (S)-salbutamol has been shown to increase bronchial hyperreactivity in animal and in vitro models, the clinical relevance of minor enantioselectivity in the peripheral lung during chronic dosing remains unclear and is the focus for future work in our research group.
